After optimizing the overall structure of Ziqiang Sheng, personnel change messages often occur.
Recently, Larry Jones, Global Vice President of Medical Technology and Group Chief Information Officer at Johnson&Johnson, announced his decision to resign. He will retire from Johnson&Johnson Medical Devices, and details such as when he will officially resign or who will take over are still unknown.

35 year veteran resigns, Johnson&Johnson personnel changes frequently
Larry Jones is an experienced veteran at Johnson&Johnson Medical, having served for 35 years. During his tenure at Johnson&Johnson's Medical Devices division, Larry Jones was particularly dedicated to driving innovation in the fields of oncology, orthopedics, cardiovascular and general surgery, and revolutionizing digital surgical connectivity solutions through advanced technologies such as surgical robots and machine learning platforms.

Larry Jones has served as the trans regional global CIO of Janssen Pharmaceuticals for more than six years. He is the executive member of the Johnson African American Leadership Committee and the Johnson Regional Leadership Committee for Diversity and Inclusion, and is also a member of the healthcare industry advisory committee of Microsoft and Verizon. In 2019, Larry Jones won the award of ITSMF and Harlem Fine Arts Association for his lifelong achievements in the field of technology. He was also nominated as InspireCIO 2019 New York/New Jersey CIO of the Year.

As a senior technology executive, Larry Jones has extensive leadership experience and has led multiple major projects in Johnson&Johnson's pharmaceutical and medical device division over the past few decades, including the recent 3-year, $200 million global digital transformation program. And his team also adheres to diversity and core values, constantly pursuing excellent employee dedication and technical execution.

In addition to Larry Jones, Johnson&Johnson Medical has also had quite frequent personnel changes in various fields over the past year.

After the radical reform and revitalization of Johnson&Johnson Group, the company has also undergone a major policy change internally. With the influx of fresh blood, Johnson&Johnson has entered a new stage of development.

Q3 performance growth, heavy acquisition landing
The purpose of rejuvenation is to promote better development of the enterprise, and under a series of reforms and changes, Johnson&Johnson also submitted its Q3 financial report recently.
Recently, Johnson&Johnson released its third quarter financial report data, with global revenue of $22.5 billion (approximately RMB 1601 billion), a year-on-year increase of 5.2%. Among them, Johnson&Johnson Medical Technology's global sales were 7.9 billion US dollars, a year-on-year increase of 5.8%. The sales growth was mainly driven by electrophysiological products and Abiomed (formerly known as interventional solutions) in the cardiovascular field, contact lenses in the vision field, and wound closure products in the general surgery field, but the growth was partially offset by internal cutting products in the advanced surgery field.

Regarding Johnson&Johnson's performance in the third quarter, Joe Wolk, Executive Vice President and Chief Financial Officer, said, "Johnson&Johnson achieved remarkable performance in the third quarter, which not only fully demonstrates the diversified advantages of our business, but also highlights our continuous innovation investment and acquisition strategy that focuses on the future and has forward-looking planning. For example, by successfully acquiring V-Wave, we have achieved differentiation and accelerated business development in our product pipeline. Looking ahead to the last quarter of 2024, we will continue to be committed to enriching and strengthening our product pipeline, laying a solid foundation for our development in 2025 and the long run.

In addition, it is not difficult to find that Johnson&Johnson has invested heavily in paving the way for its cardiovascular business in recent years. In just three years, Johnson&Johnson has acquired four cardiovascular equipment companies, enhancing its strength in the cardiovascular field. Currently, Johnson&Johnson's acquisition amount in this field has exceeded 30 billion US dollars.
Abiomed, which made a significant contribution to Q3 business, was also acquired. In November 2022, Johnson&Johnson announced its intention to acquire Abiomed through an all cash transaction at a prepaid price of $380 per share. The previous valuation, including cash, amounted to $16.6 billion. It is worth noting that this is also the largest acquisition by Johnson&Johnson in the cardiovascular field.

In addition to Abiomed, Johnson&Johnson has also made progress in its acquisitions in the cardiovascular field this year. On October 9th, Johnson&Johnson announced the completion of the acquisition of V-Wave, a manufacturer of atrial shunts. V-Wave's main product, the Ventura atrial shunt, is an implantable device used to treat heart failure. This technology reduces left atrial pressure in patients with congestive heart failure by establishing a shunt between the left and right atria of the heart, thereby reducing cardiovascular events and hospitalization rates for heart failure.

The addition of V-Wave will enable Johnson&Johnson to provide more diverse and effective treatments for heart failure, meeting the unmet needs of approximately 800000 patients with heart failure with reduced ejection fraction (HFrEF) annually.

Source: https://news.yaozh.com/archive/44498.html